title: Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.
abstract: Persistence of Mycobacterium tuberculosis remains a significant challenge for the effective treatment of tuberculosis in humans. In animals that develop necrotic lung lesions following infection with M. tuberculosis, drug-tolerant bacilli are present and persist in an extracellular microenvironment within the necrotic cores. In this study, we examined the efficacy of drug treatment in C3HeB/FeJ (Kramnik) mice that develop lesions with liquefactive necrosis, in comparison to BALB/c mice that develop nonnecrotic lesions following aerosol challenge. To accomplish this, Kramnik and BALB/c mice were infected by aerosol with M. tuberculosis and treated for 7 to 8 weeks with monotherapy using drugs with different modes of action. The efficacy of drug therapy was quantified by enumeration of bacterial load. The progression of disease and location and distribution of bacilli within lesions were visualized using various staining techniques. In the late stages of infection, Kramnik mice developed fibrous encapsulated lung lesions with central liquefactive necrosis containing abundant extracellular bacilli, whereas BALB/c mice formed nonnecrotic lesions with primarily intracellular bacilli. Necrotic lesions in Kramnik mice showed evidence of hypoxia by pimonidazole staining. Kramnik mice were significantly more refractory to drug therapy, especially for pyrazinamide. Metronidazole showed no bactericidal activity in either model. There were significantly higher numbers of drug-resistant colonies isolated from the Kramnik mice compared to BALB/c mice. These results suggest that the Kramnik mouse model will be a valuable model to test antituberculosis drugs, especially against bacilli that persist within necrotic lesions.
authors.affiliation: Mycobacterial Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, Colorado, USA.
authors.forename: Emily R
authors.initials: ER
authors.lastname: Driver
authors.forename: Gavin J
authors.initials: GJ
authors.lastname: Ryan
authors.forename: Donald R
authors.initials: DR
authors.lastname: Hoff
authors.forename: Scott M
authors.initials: SM
authors.lastname: Irwin
authors.forename: Randall J
authors.initials: RJ
authors.lastname: Basaraba
authors.forename: Igor
authors.initials: I
authors.lastname: Kramnik
authors.forename: Anne J
authors.initials: AJ
authors.lastname: Lenaerts
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006099:Granuloma / Q000188:drug therapy* / Q000382:microbiology*; D008795:Metronidazole / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000472:pathogenicity*; D011718:Pyrazinamide / Q000627:therapeutic use
chemical_list: D000995:Antitubercular Agents; D008795:Metronidazole; D011718:Pyrazinamide